Skip to main content

Table 3 Secondary parameters of piperaquine pharmacokinetics in pregnant and non-pregnant women with uncomplicated P . falciparum malaria

From: A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan

Secondary parameters

Total

Non-pregnant women

Pregnant women

p-value

CMAX (ng/mL)

158 [40.6-363]

102 [40.6-235]

185 [109–363]

0.021

TMAX (hours)

2.62 [0.887-4.64]

1.48 [0.887-4.18]

3.07 [1.65-4.64]

0.018

Half-life (days)

23.4 [19.1-33.3]

25.7 [20.9-33.3]

22.1 [19.1-25.8]

0.001

Day 7 concentration (ng/mL)

58.3 [16.6-146]

55.4 [16.6-146]

60.7 [40.1-103]

0.671

Day 28 concentration (ng/mL)

15.9 [4.85-38.6]

15.4 [4.85-38.6]

16.1 [9.68-26.8]

0.840

AUC0->90 (ng*h/mL)

40600 [12400–100000]

38000 [12400–100000]

42700 [27100–68700]

0.799

AUC48h->90 (ng*h/mL)

36400 [10600–90300]

35300 [10600–90300]

37700 [23500–63200]

0.887

  1. Secondary parameters are predicted using the final model and values are presented as median [range]. The p-values are calculated with a Mann–Whitney U-test.
  2. CMAX is the predicted maximum concentration after the first dose and TMAX is the time to CMAX. Half-life is the estimated terminal elimination half-life. Day 7 and 28 concentrations are the model predicted plasma concentrations of piperaquine at day 7 and 28, respectively. AUC0->90 is the predicted area under the concentration-time curve from time zero extrapolated to day 90. AUC48h->90 is the predicted area under the concentration-time curve from 48 hours extrapolated to day 90.